FDA Approves IDE study assessing Revita for weight maintenance after discontinuation of GLP-1The FDA has approved a pivotal Investigational Device Exemption (IDE) to study the efficacy of Fractyl Health’s Revita system for...
Tirzepatide found to reduce body weight regardless of duration of condition and BMI before treatment1 day ago